Molecular Therapy - Oncolytics

Slides:



Advertisements
Similar presentations
Volume 5, Issue 3, Pages (March 2002)
Advertisements

Volume 10, Issue 2, Pages (August 2004)
Molecular Therapy - Oncolytics
Molecular Therapy - Oncolytics
Immunologic Characterization of HIV-Specific DNA Vaccine
Upregulation of Inflammatory Cytokines and Oncogenic Signal Pathways Preceding Tumor Formation in a Murine Model of T-Cell Lymphoma in Skin  Xuesong Wu,
Molecular Therapy - Methods & Clinical Development
Targeting an Oncolytic Influenza A Virus to Tumor Tissue by Elastase
Maternal-Derived Hepatitis B Virus e Antigen Alters Macrophage Function in Offspring to Drive Viral Persistence after Vertical Transmission  Yongjun Tian,
Volume 16, Issue 3, Pages (March 2008)
Molecular Therapy - Methods & Clinical Development
Molecular Therapy - Methods & Clinical Development
Volume 21, Issue 3, Pages (March 2013)
Molecular Therapy - Oncolytics
Molecular Therapy - Oncolytics
Beatriz Silva Lima, Mafalda Ascensão Videira 
Molecular Therapy - Nucleic Acids
Oncolytic Immunotherapy for Bladder Cancer Using Coxsackie A21 Virus
A Recombinant Baculovirus Efficiently Generates Recombinant Adeno-Associated Virus Vectors in Cultured Insect Cells and Larvae  Yang Wu, Liangyu Jiang,
Volume 15, Issue 2, Pages (February 2007)
Volume 25, Issue 4, Pages (April 2017)
Volume 26, Issue 9, Pages (September 2018)
Volume 18, Issue 9, Pages (September 2010)
Volume 17, Issue 2, Pages (February 2009)
Molecular Therapy - Methods & Clinical Development
Codon-Optimized P1A-Encoding DNA Vaccine: Toward a Therapeutic Vaccination against P815 Mastocytoma  Alessandra Lopes, Kevin Vanvarenberg, Véronique Préat,
Volume 22, Issue 1, Pages (January 2014)
Incorporation of the B18R Gene of Vaccinia Virus Into an Oncolytic Herpes Simplex Virus Improves Antitumor Activity  Xinping Fu, Armando Rivera, Lihua.
Reovirus FAST Protein Enhances Vesicular Stomatitis Virus Oncolytic Virotherapy in Primary and Metastatic Tumor Models  Fabrice Le Boeuf, Simon Gebremeskel,
Volume 23, Issue 10, Pages (October 2015)
Efficacy and Safety of Doubly-Regulated Vaccinia Virus in a Mouse Xenograft Model of Multiple Myeloma  Muneyoshi Futami, Kota Sato, Kanji Miyazaki, Kenshi.
Molecular Therapy - Methods & Clinical Development
Exosomes from M1-Polarized Macrophages Potentiate the Cancer Vaccine by Creating a Pro-inflammatory Microenvironment in the Lymph Node  Lifang Cheng,
piggyBac Transposon-mediated Long-term Gene Expression in Mice
Modular Three-component Delivery System Facilitates HLA Class I Antigen Presentation and CD8+ T-cell Activation Against Tumors  Benjamin J Umlauf, Chin-Ying.
Volume 8, Issue 16, Pages R551-R553 (July 1998)
Increased Expression of Laminin Subunit Alpha 1 Chain by dCas9-VP160
Lukxmi Balathasan, Vera A
Molecular Therapy - Oncolytics
Volume 29, Issue 6, Pages (June 2016)
Volume 13, Issue 1, Pages (January 2006)
Sangeet Lal, Corey Raffel  Molecular Therapy - Oncolytics 
Volume 26, Issue 2, Pages (February 2018)
Volume 25, Issue 11, Pages (November 2017)
Volume 20, Issue 3, Pages (March 2012)
Volume 26, Issue 1, Pages (January 2018)
Volume 17, Issue 10, Pages (October 2009)
Molecular Therapy - Nucleic Acids
Volume 9, Issue 3, Pages (March 2004)
Molecular Therapy - Oncolytics
Volume 25, Issue 4, Pages (April 2017)
Volume 15, Issue 5, Pages (May 2007)
Volume 26, Issue 4, Pages (April 2018)
Quan Jin, Chunping Qiao, Jianbin Li, Juan Li, Xiao Xiao 
Single-Shot, Multicycle Suicide Gene Therapy by Replication-Competent Retrovirus Vectors Achieves Long-Term Survival Benefit in Experimental Glioma  Chien-Kuo.
The Expression of MicroRNA-598 Inhibits Ovarian Cancer Cell Proliferation and Metastasis by Targeting URI  Feng Xing, Shuo Wang, Jianhong Zhou  Molecular.
Volume 20, Issue 4, Pages (April 2012)
Molecular Therapy - Oncolytics
Fetal Brain-directed AAV Gene Therapy Results in Rapid, Robust, and Persistent Transduction of Mouse Choroid Plexus Epithelia  Marie Reine Haddad, Anthony.
Molecular Therapy - Nucleic Acids
Volume 19, Issue 6, Pages (May 2017)
Volume 2, Issue 4, Pages (October 2002)
Development of a Safe and Effective Vaccinia Virus Oncolytic Vector WR-Δ4 with a Set of Gene Deletions on Several Viral Pathways  Ernesto Mejías-Pérez,
Tatiana Zavorotinskaya, Adrian Tomkinson, John E Murphy 
Evidence for Encapsidation of Prokaryotic Sequences during Recombinant Adeno- Associated Virus Production and Their in Vivo Persistence after Vector Delivery 
CD28 Aptamers as Powerful Immune Response Modulators
Volume 15, Issue 9, Pages (September 2007)
Biao Dong, Hiroyuki Nakai, Weidong Xiao  Molecular Therapy 
Deletion of Apoptosis Inhibitor F1L in Vaccinia Virus Increases Safety and Oncolysis for Cancer Therapy  Adrian Pelin, Johann Foloppe, Julia Petryk, Ragunath.
Molecular Therapy - Methods & Clinical Development
Presentation transcript:

Molecular Therapy - Oncolytics Recombinant AAV-CEA Tumor Vaccine in Combination with an Immune Adjuvant Breaks Tolerance and Provides Protective Immunity  Jonathan A. Hensel, Vinayak Khattar, Reading Ashton, Selvarangan Ponnazhagan  Molecular Therapy - Oncolytics  Volume 12, Pages 41-48 (March 2019) DOI: 10.1016/j.omto.2018.12.004 Copyright © 2018 The Authors Terms and Conditions

Figure 1 Characterization of Recombinant-AAV Expressing Human CEA, the C57BL/6 Syngeneic Cell Line MC38-CEA, and the Experimental Outline (A) The rAAV-CEA construct was developed by sub-cloning the human CEA70 open reading frame under the control of cytomegalovirus (CMV)-chicken beta-actin promoter and poly(A) sequence within AAV1 inverted terminal repeats. (B) Western blotting for CEA expression in HEK293 cells, either transfected with pAAV-CEA or transduced with rAAV-CEA. Western blot images presented are a composite of results from two different blots, in each box. In the plasmid transfection experiment (left), the same blot was used for staining with CEA and GAPDH antibodies in succession. (C) Flow cytometry of CEA expression in C57BL/6 syngeneic colon cancer cell lines: MC38 parental cells (blue histogram) and MC38-CEA (red histogram). (D) Overall experimental schema: on day 1, mice were either unvaccinated or intramuscularly vaccinated once with either rAAV-GFP or rAAV-CEA (2 × 1011 virus particles per mouse). Following vector vaccinations, on days 11, 18 and 25, mice were given 50 μg GM-CSF at the rAAV vaccination sites. On day 31, mice were challenged with 4 × 105 syngeneic MC38-CEA cells. Molecular Therapy - Oncolytics 2019 12, 41-48DOI: (10.1016/j.omto.2018.12.004) Copyright © 2018 The Authors Terms and Conditions

Figure 2 Immunohistochemistry for CEA Expression and Immune Infiltrates at the Site of Vaccination (A) Immunohistochemistry for CEA was performed in muscle tissue of rAAV-GFP or -CEA-vaccinated mice. (B) Muscle tissues from mice that received rAAV-CEA alone or rAAV-CEA + pGM-CSF immune adjuvant were fixed and stained by immunohistochemistry with CD45 antibody for overall immune infiltrates and with F4/80 antibody for macrophages in particular. Molecular Therapy - Oncolytics 2019 12, 41-48DOI: (10.1016/j.omto.2018.12.004) Copyright © 2018 The Authors Terms and Conditions

Figure 3 ELISA for CEA as a Measure of Breaking Tolerance to a Self Antigen CEA ELISA was performed in replicates using serum samples from naive mice and mice that received rAAV-CEA + pGM-CSF adjuvant (n = 3). **p < 0.01; ***p < 0.001. Molecular Therapy - Oncolytics 2019 12, 41-48DOI: (10.1016/j.omto.2018.12.004) Copyright © 2018 The Authors Terms and Conditions

Figure 4 Tumor-free Survival in Response to rAAV-CEA Vaccine Plus pGM-CSF Following rAAV-CEA vaccination and application of pGM-CSF at the site of vector administration, when optimal CEA expression was achieved, mice were challenged with CEA-expressing, syngeneic MC38-CEA cells (4 × 105) in the flank region. Tumor-free survival of naive, rAAV-GFP + pGM-CSF, or rAAV-CEA + pGM-CSF mice was recorded well beyond the time when mice in control groups had developed tumors (n = 5). **p < 0.01. Molecular Therapy - Oncolytics 2019 12, 41-48DOI: (10.1016/j.omto.2018.12.004) Copyright © 2018 The Authors Terms and Conditions

Figure 5 Expression of CEA by MC38 Parental Cells and CEA-Expressing MC38-CEA Cells and Tumor Challenge Study with MC38 Parental Cells following rAAV-CEA + pGM-CSF Adjuvant Applications (A) CEA expression on MC38 parental cells was compared to that expressed by MC38-CEA cells to confirm lack of CEA expression by parental cells. (B) Cohorts of naive mice, mice that received pGM-CSF adjuvant injections only, or mice that were vaccinated with rAAV-CEA plus pGM-CSF adjuvant injections were tumor challenged with MC38 parental cells (4 × 105) and assessed for tumor development, starting 1 week post-tumor challenge (n ≥ 3). Molecular Therapy - Oncolytics 2019 12, 41-48DOI: (10.1016/j.omto.2018.12.004) Copyright © 2018 The Authors Terms and Conditions